scholarly journals MP27-03 HYPERMETHYLATION OF THE RASSF1A GENE PROMOTER AT CYTOSINE GUANINE DINUCLEOTIDE ISLANDS PREDICTS HIGHER MALIGNANT POTENTIAL BUT BETTER URINARY TRACT RECURRENCE-FREE SURVIVAL IN UPPER TRACT UROTHELIAL CARCINOMA PATIENTS AFTER SURGERY

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Jin Liu ◽  
Gengyan Xiong ◽  
Qi Tang ◽  
Dong Fang ◽  
Xuesong Li ◽  
...  
2014 ◽  
Vol 32 (5) ◽  
pp. 619-624 ◽  
Author(s):  
Patrick N. Espiritu ◽  
Einar F. Sverrisson ◽  
Wade J. Sexton ◽  
Julio M. Pow-Sang ◽  
Michael A. Poch ◽  
...  

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Patrick N. Espiritu ◽  
Einar F. Sverrisson ◽  
Wade J. Sexton ◽  
Julio M. Pow-Sang ◽  
Michael A. Poch ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Zai-Lin Sheu ◽  
Chi-Ping Huang ◽  
Chao-Hsiang Chang ◽  
Chung-Hsin Chen ◽  
Jian-Hua Hong ◽  
...  

AbstractTumor multifocality and location are prognostic factors for upper tract urothelial carcinoma (UTUC). However, confounding effects can appear when these two factors are analyzed together. Therefore, we aimed to investigate the impact of tumor distribution on the outcomes of multifocal UTUC after radical nephroureterectomy. From the 2780 UTUC patients in the Taiwan UTUC Collaboration Group, 685 UTUC cases with multifocal tumors (defined as more than one tumor lesion in unilateral upper urinary tract) were retrospectively included and divided into three groups: multiple renal pelvic tumors, multiple ureteral tumors, and synchronous renal pelvic and ureteral tumors included 164, 152, and 369 patients, respectively. We found the prevalence of carcinoma in situ was the highest in the synchronous group. In multivariate survival analyses, tumor distribution showed no difference in cancer-specific and disease-free survival, but there was a significant difference in bladder recurrence-free survival. The synchronous group had the highest bladder recurrence rate. In summary, tumor distribution did not influence the cancer-specific outcomes of multifocal UTUC, but synchronous lesions led to a higher rate of bladder recurrence than multiple renal pelvic tumors. We believe that the distribution of tumors reflects the degree of malignant involvement within the urinary tract, but has little significance for survival or disease progression.


2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Nir Kleinmann ◽  
Phillip Pierorazio ◽  
Jay Raman ◽  
Scott Hubosky ◽  
Ahmad Shabsigh ◽  
...  

PeerJ ◽  
2016 ◽  
Vol 4 ◽  
pp. e2063 ◽  
Author(s):  
Su Zhang ◽  
You Luo ◽  
Cheng Wang ◽  
Sheng-Jun Fu ◽  
Li Yang

Background.Several factors have been validated as predictors of disease recurrence in upper tract urothelial carcinoma. However, the oncological outcomes between different surgical approaches (open nephroureterectomy versus laparoscopic nephroureterectomy, ONU vs LNU) remain controversial. Therefore, we performed a meta-analysis to evaluate the oncological outcomes associated with different surgical approaches.Methods.We conducted an electronic search of the PubMed, Embase, ISI Web of Knowledge and Cochrane Library electronic databases through November 2015, screened the retrieved references, collected and evaluated the relevant information. We extracted and synthesized the corresponding hazard ratios (HRs) and 95% confidence intervals (95% CI) using Stata 13.Results.Twenty-one observational studies were eligible for inclusion in the meta-analysis. The results of the meta-analysis showed no differences in the intravesical recurrence-free survival (IRFS), unspecified recurrence-free survival (UnRFS) and overall survival (OS) between LNUandONU. However, improvements in the extravesical recurrence free survival (ExRFS) and cancer specific survival (CSS) were observed inLNU. The pooled hazard ratios were 1.05 (95% CI [0.92–1.18]) for IRFS, 0.80 (95% CI [0.64–0.96]) for ExRFS, 1.10 (95% CI [0.93–1.28]) for UnRFS, 0.91 (95% CI [0.66–1.17]) for OS and 0.79 (95% CI [0.68–0.91]) for CSS.Conclusion.Based on current evidence, LNU could provide equivalent prognostic effects for upper tract urothelial carcinoma, and had better oncological control of ExRFS and CSS compared to ONU. However, considering all eligible studies with the intrinsic bias of retrospective study design, the results should be interpreted with caution. Prospective randomized trials are needed to verify these results.


Sign in / Sign up

Export Citation Format

Share Document